The 50th edition of the leading clinical reference on treatment of infectious diseases and anti-infective drug information. Helpful in day-to-day practice and as a component of your organization's antimicrobial stewardship program, The Sanford Guide provides valuable guidance in the age of antibiotic resistance. Popular with physicians, pharmacists, physician assistants, nurse practitioners, and other clinicians, The Sanford Guide to Antimicrobial Therapy provides information that is convenient, concise, and reliable.

Coverage includes:
　ㆍ Clinical syndromes
　　　ㅿ pathogens
　　　ㅿ bacterial
　　　ㅿ fungal
　　　ㅿ mycobacterial
　　　ㅿ parasitic
　　　ㅿ viral

　ㆍ Anti-infective agents
　　　ㅿ dosing
　　　　　　≫ pediatric adjustments
　　　　　　≫ renal adjustments
　　　ㅿ adverse affects
　　　ㅿ activity
　　　ㅿ pharmacology
　　　ㅿ interactions
　ㆍ Preventative therapy

What's new in 2020:

　　▣ Table 1: Osteomyelitis, meningitis, amnionitis, gastric ulcer, traveler’s diarrhea, C. difficile, keratitis, epididymo-orchitis, septic arthritis, prosthetic joint infection, pneumonia (empiric: age-determined, CAP, HAP, VAP; and specific, esp. GNB); secondary peritonitis, pharyngitis, parapharyngeal space infection, ulcerated skin, bacillary angiomatosis, thrombophlebitis
　　▣ Table 2: Updated treatment options overview, especially gram-negative bacilli
　　▣ Table 3: Duration of therapy: bacteremia, bone, genital, intra-abdominal, kidney
　　▣ Table 4: New drugs and updates reflecting shifting susceptibility/resistance patterns
　　▣ Table 5: Highly resistant bacteria, especially GNB
　　▣ Table 6: MRSA
　　▣ Table 7: New desensitization protocols
　　▣ Table 8: Pregnancy risk & lactation safety for new drugs
　　▣ Table 9: PK & interactions data for new drugs
　　▣ Table 10: New antibacterials, including cefidericol, imipenem-cilastatin-relebactam, lefamulin and drug information for agents available in other regions, e.g., IV forsfomycin
　　▣ Table 11: Updated recommendations, including Candida auris
　　▣ Table 12: Updated recommendations for MDR tuberculosis and non-tuberculous mycobacteria
　　▣ Table 13: Updated recommendations and drug availability for intestinal protozoa, malaria, trypanosomiasis, worms
　　▣ Table 14: Adenovirus, coronavirus (2019-nCoV), Ebola, Epstein-Barr virus, neonatal herpes, influenza, measles; HIV - new ARVs
　　▣ Table 15: Surgical prophylaxis
　　▣ Table 16: Updated pediatric dosing for new and older drugs
　　▣ Table 17: Renal impairment adjustments for new and some older drugs; updated obesity dosing
　　▣ Table 22: Drug-drug interactions updates for new and existing antimicrobials